Search
Carafiban
go.drugbank.com/drugs/DB19813ExperimentalThe usage of the INN stem '-fiban' in the name indicates that Carafiban is a fibrinogen receptor antagonist (glycoprotein IIb/IIIa receptor antagonist).
Licostinel
go.drugbank.com/drugs/DB19864ExperimentalThe usage of the INN stem '-stinel' in the name indicates that Licostinel is a N-methyl-D-aspartate (NMDA) receptor co-agonist. Licostinel has a monoisotopic molecular weight of 274.95 Da.
Orbofiban
go.drugbank.com/drugs/DB20676ExperimentalThe usage of the INN stem '-fiban' in the name indicates that Orbofiban is a fibrinogen receptor antagonist (glycoprotein IIb/IIIa receptor antagonist).
Gantofiban
go.drugbank.com/drugs/DB20951ExperimentalThe usage of the INN stem '-fiban' in the name indicates that Gantofiban is a fibrinogen receptor antagonist (glycoprotein IIb/IIIa receptor antagonist).
Roxifiban
go.drugbank.com/drugs/DB21089ExperimentalThe usage of the INN stem '-fiban' in the name indicates that Roxifiban is a fibrinogen receptor antagonist (glycoprotein IIb/IIIa receptor antagonist).
Sibrafiban
go.drugbank.com/drugs/DB21420ExperimentalThe usage of the INN stem '-fiban' in the name indicates that Sibrafiban is a fibrinogen receptor antagonist (glycoprotein IIb/IIIa receptor antagonist).
Zerencotrep
go.drugbank.com/drugs/DB21710ExperimentalThe usage of the INN stem '-cotrep' in the name indicates that Zerencotrep is a transient receptor potential canonical channel 5 (TRPC5) antagonist.
Dexamethasone isonicotinate
go.drugbank.com/drugs/DB11487ExperimentalVet approvedDexamethasone isonicotinate is an anti-inflammatory, anti-allergic glucocorticoid that can be administered orally, by inhalation, topically, and parenterally.
Berzosertib
go.drugbank.com/drugs/DB11794InvestigationalBerzosertib (VX-970) has been used in trials studying the treatment of Ovarian Neoplasms, Ovarian Serous Tumor, Adult Solid Neoplasm, Advanced Solid Tumor, and Advanced Solid Neoplasm, among others.
Tesidolumab
go.drugbank.com/drugs/DB11926InvestigationalTesidolumab has been used in trials studying the treatment of Geographic Atrophy, Non-infectious Panuveitis, Exudative Macular Degeneration, Non-infectious Posterior Uveitis, and Age-related Macular Degeneration